Company
CNSX:BIOV
Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early-stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
39 stories · page 2 of 2
The biotech said a study completed on inhibition of ACE-2 binding activity on its coronavirus vaccine candidate BVX-0320 shows it has superior cardiac safety compared to existing mRNA and Adenovirus Vector vaccines
The biotech company issued 2,680,000 units at a price of $0.15 each for gross proceeds of $402,000 in the first tranche
The company said it intends to use the net proceeds of the offering for working capital purposes
The collaboration will leverage BioVaxys' proprietary haptenized viral antigen platform to create a broadly reactive pan-sarbecovirus vaccine
The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is planning a clinical trial of its haptenized autologous tumor cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhi
The company’s CoviDTH, is a diagnostic tool for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19
The company’s CoviDTH, is a diagnostic tool for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19
Although CoviDTH diagnostic results are intended to be visually interpreted, additional patent claims include data capture and analysis via optical, infrared, and ultrasonic images processing methods.
The Vancouver-based biotech company plans on leveraging its invention to immunize people who have either recovered from the coronavirus (COVID-19) infection, or have been fully vaccinated
The company will highlight the SARS-Cov-2 spike protein vaccine induced strong antibody and T cell responses in a murine model
The Vancouver-based clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics also provided an update regarding a March 2021 agreement with Inotiv Inc, a global contract research org
The study will zero in on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BioVaxys’ COVID-19 vaccine candidate BVX-0320
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Bio Elpida has completed the technology process transfer with BioVaxys and started the development phase using a ‘quality by design’ approach, which includes establishing the control methods and manufacturing process development
BVX-0320 is BioVaxys’ COVID-19 vaccine candidate with CoviDTH its immunodiagnostic product -- and both are headed for clinical trials
Study results showed that the DTH test can be used as a routine diagnostic method to monitor the T cell-mediated response to SARS-CoV-2
Dr Yvelise Barrios, who has led the two clinical studies in Spain’s Hospital Universitario de Canarias, will be a scientific adviser at BioVaxys
The company now will draft an IND application to support a Phase I/II safety, dosing, and efficacy study of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2
The aggregate private placement consists of the sale of up to 9,090,909 units for total gross proceeds of about $2 million
